Clinical Trial

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (Protocol v.00)

MOA: Dabrafenib is a RAF kinase inhibitor. Trametinib is an allosteric inhibitor of MEK1/2 and kinase activity.

Key Eligibility:

• Documented BRAF V600E mutation-positive solid tumor
• Study participants previously not treated with dabrafenib and/or trametinib (or other BRAF and/or MEK inhibitor(s)).
  • Study participants who received dabrafenib and trametinib in the past for the treatment of other malignancies are eligible if treatment has been discontinued for >1 year
• Ability to provide scans for central imaging review
• Patients with NSCLC, melanoma, ATC, BTC, Glioma, and
  CRC are excluded